| This week's sponsor is INC Research. | | | |
Top Stories Monday, October 31, 2016 Sanofi and partner Regeneron have become the latest biopharmas to be hit by a complete response letter from the FDA this year for manufacturing concerns as its experimental arthritis med sarilumab now faces months of delay. Monday, October 31, 2016 Healthcare investment firm Third Rock Ventures has closed its “Fund IV,” raising $616 million in what was an oversubscribed fund, as it also bolsters its team with Novartis and Eleven Biotherapeutics alumni Abbie Celniker. Monday, October 31, 2016 Just a few months after posting early-stage data for its experimental brain cancer med GDC-0084, Roche has handed over development rights for the drug to Australian upstart biotech Novogen. Monday, October 31, 2016 Berg has expanded its alliance with the U.S. Department of Defense to cover research into breast cancer. The biotech will apply its technology platform to serum and tissue samples covering several breast cancer subtypes in an attempt to find molecular signatures that aid understanding of the disease. Monday, October 31, 2016 Medtronic is trumpeting positive results from a clinical trial of one of its drug-eluting stents, a boon for the company as it competes in a crowded market. | This week's sponsor is MedNet. | | | Successfully Managing Registries with eClinical Technology
Free case study: See how eClinical technology supported a disease-specific Registry, ensuring the quick attainment of enrollment goals and the creation of multiple publications. Download now. |
| | | Epizyme teams up with NCI for work on its cancer meds: tazemetostat, an EZH2 inhibitor, and pinometostat, its first-in-class DOT1L inhibitor. Release The FDA has accepted Ariad’s NDA for its oral ALK inhibitor brigatinib in certain lung cancer patients. Release Eisai and partner Biogen have kick-started a Phase III test for BACE inhibitor E2609 in early-stage Alzheimer’s. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented by: Covance The role of health economic data has never been more important. Presented by: Covance Leading manufacturers increasingly employ stakeholder research early in development to better identify the needs of patients and providers. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. CBI’s 7th West Coast Compliance Congress November 9-10, 2016 | San Francisco, CA PepTalk: The Protein Science Week January 9-13, 2017 | San Diego, CA Drug Development Boot CampTM 2016 November 16-17, 2016 | Boston, MA Fierce Innovation Awards: Life Sciences Edition 2016 Application Deadline: Monday, December 2nd Cannabis-Based Therapies November 30–December 1, 2016 | San Francisco, CA Discover the Richness of Latin America November 29–30, 2016 | San Juan, Puerto Rico Clinical Diagnostics & Research November 2-3, 2016 Master of Science in Bioinformatics at Northeastern University Fall 2016, Spring 2017 Courses 24th International Molecular Medicine Tri-Conference February 19-24, 2014 | Moscone North Convention Center | San Francisco, CA | 